{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:42:31Z","timestamp":1784238151119,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1029901"],"award-info":[{"award-number":["1029901"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Androgen deprivation therapy (ADT) in men with prostate cancer (PCa) results in adverse effects, including reduced muscle strength and physical function, potentially compromising daily functioning. We examined whether it was more efficacious to commence exercise at the onset of ADT rather than later in treatment to counter declines in strength and physical function.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>One-hundred-and-four men with PCa (68.3\u2009\u00b1\u20097.0 years) initiating ADT were randomised to immediate exercise (IMX, <jats:italic>n<\/jats:italic>\u2009=\u200954) or delayed exercise (DEL, <jats:italic>n<\/jats:italic>\u2009=\u200950) for 12 months. IMX comprised 6 months of supervised resistance\/aerobic\/impact exercise initiated at the onset of ADT with a 6-month follow-up. DEL comprised 6 months of usual care followed by 6 months of resistance\/aerobic\/impact exercise. Upper and lower body muscle strength and physical function were assessed at baseline, 6 and 12 months.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>There was a significant difference for all strength measures at 6 months favouring IMX (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), with net differences in leg press, seated row and chest press strength of 19.9\u2009kg (95% CI, 12.3\u201327.5\u2009kg), 5.6\u2009kg (3.8\u20137.4\u2009kg) and 4.3\u2009kg (2.7\u20135.8\u2009kg), respectively. From 7 to 12 months, DEL increased in all strength measures (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), with no differences between groups at 12 months. Similarly, physical function improved (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) in IMX compared with DEL at 6 months for the 6-m fast walk (\u22120.2, 95% CI \u22120.3 to \u22120.1\u2009s), 400-m walk (\u22129.7, \u221214.8 to \u22124.6\u2009s), stair climb (\u22120.4, \u22120.6 to \u22120.2\u2009s) and chair rise (\u22121.0, \u22121.4 to \u22120.7\u2009s), with no differences between groups by 12 months, except for the 6-m fast walk (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Exercise either at the onset or after 6 months of ADT preserves\/enhances muscle strength and physical function. However, to avoid initial treatment-related adverse effects on strength and function, exercise therapy should be implemented with initiation of ADT.<\/jats:p>\n<\/jats:sec>","DOI":"10.1038\/s41391-019-0200-z","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T11:02:47Z","timestamp":1580814167000},"page":"457-464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Timing of exercise for muscle strength and physical function in men initiating ADT for prostate cancer"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0302-6129","authenticated-orcid":false,"given":"Robert U.","family":"Newton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Galv\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Spry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne K.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickon","family":"Hayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis R.","family":"Taaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"issue":"Suppl 1","key":"200_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0090-4295(02)01560-1","volume":"60","author":"MV Meng","year":"2002","unstructured":"Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology. 2002;60 (Suppl 1):7\u201311.","journal-title":"Urology"},{"key":"200_CR2","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/cncr.31153","volume":"124","author":"DJ McHugh","year":"2018","unstructured":"McHugh DJ, Root JC, Nelson CJ, Morris MJ. Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: how much smoke and how much fire? Cancer. 2018;124:1326\u201334.","journal-title":"Cancer"},{"key":"200_CR3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.ejca.2006.01.029","volume":"42","author":"NA Spry","year":"2006","unstructured":"Spry NA, Kristjanson L, Hooton B, Hayden L, Neerhut G, Gurney H, et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer. 2006;42:1083\u201392.","journal-title":"Eur J Cancer"},{"key":"200_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S, D\u2019Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825\u201336.","journal-title":"Eur Urol"},{"issue":"Suppl 5","key":"200_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bju.12964","volume":"115","author":"H Rhee","year":"2015","unstructured":"Rhee H, Gunter JH, Heathcote P, Ho K, Stricker P, Corcoran NM, et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int. 2015;115 (Suppl 5):3\u201313.","journal-title":"BJU Int"},{"key":"200_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1464-410X.2008.07539.x","volume":"102","author":"DA Galvao","year":"2008","unstructured":"Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102:44\u201347.","journal-title":"BJU Int"},{"key":"200_CR7","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2011.38.8850","volume":"30","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30:3271\u20136.","journal-title":"J Clin Oncol"},{"key":"200_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","volume":"56","author":"S Basaria","year":"2002","unstructured":"Basaria S, Lieb J, Tang AM, DeWeese T, Carducci M, Eisenberger M, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf). 2002;56:779\u201386.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"200_CR9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2522\/ptj.20060302","volume":"87","author":"CA Clay","year":"2007","unstructured":"Clay CA, Perera S, Wagner JM, Miller ME, Nelson JB, Greenspan SL. Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther. 2007;87:1325\u201333.","journal-title":"Phys Ther"},{"key":"200_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.urology.2008.03.032","volume":"72","author":"K Bylow","year":"2008","unstructured":"Bylow K, Dale W, Mustian K, Stadler WM, Rodin M, Hall W, et al. Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology. 2008;72:422\u20137.","journal-title":"Urology"},{"key":"200_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/pcan.2008.51","volume":"12","author":"DA Galv\u00e3o","year":"2009","unstructured":"Galv\u00e3o DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 2009;12:198\u2013203.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"200_CR12","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1200\/JCO.2010.29.8091","volume":"28","author":"SM Alibhai","year":"2010","unstructured":"Alibhai SM, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol. 2010;28:5038\u201345.","journal-title":"J Clin Oncol"},{"key":"200_CR13","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1200\/JCO.2003.09.534","volume":"21","author":"RJ Segal","year":"2003","unstructured":"Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21:1653\u20139.","journal-title":"J Clin Oncol"},{"key":"200_CR14","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1249\/01.mss.0000233803.48691.8b","volume":"38","author":"DA Galvao","year":"2006","unstructured":"Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38:2045\u201352.","journal-title":"Med Sci Sports Exerc"},{"key":"200_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2009.23.2488","volume":"28","author":"DA Galvao","year":"2010","unstructured":"Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28:340\u20137.","journal-title":"J Clin Oncol"},{"key":"200_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bju.12646","volume":"115","author":"P Cormie","year":"2015","unstructured":"Cormie P, Galvao DA, Spry N, Joseph D, Chee R, Taaffe DR, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2015;115:256\u201366.","journal-title":"BJU Int"},{"key":"200_CR17","doi-asserted-by":"publisher","first-page":"909916","DOI":"10.1136\/bjsports-2010-082719","volume":"46","author":"KL Campbell","year":"2012","unstructured":"Campbell KL, Neil SE, Winters-Stone KM. Review of exercise studies in breast cancer survivors: attention to principles of exercise training. Br J Sports Med. 2012;46:909916.","journal-title":"Br J Sports Med"},{"key":"200_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/bju.14505","volume":"123","author":"DR Taaffe","year":"2019","unstructured":"Taaffe DR, Galv\u00e3o DA, Spry N, Joseph D, Chambers SK, Gardiner RA, et al. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition. BJU Int. 2019;123:261\u20139.","journal-title":"BJU Int"},{"key":"200_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-432","volume":"12","author":"RU Newton","year":"2012","unstructured":"Newton RU, Taaffe DR, Spry N, Cormie P, Chambers SK, Gardiner RA, et al. Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation? BMC Cancer. 2012;12:432.","journal-title":"BMC Cancer"},{"key":"200_CR20","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/j.1532-5415.1999.tb05201.x","volume":"47","author":"DR Taaffe","year":"1999","unstructured":"Taaffe DR, Duret C, Wheeler S, Marcus R. Once-weekly resistance exercise improves muscle strength and neuromuscular performance in older adults. J Am Geriatr Soc. 1999;47:1208\u201314.","journal-title":"J Am Geriatr Soc"},{"key":"200_CR21","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1111\/j.1532-5415.2005.00494.x","volume":"53","author":"DA Galv\u00e3o","year":"2005","unstructured":"Galv\u00e3o DA, Taaffe DR. Resistance exercise dosage in older adults: single versus multiset effects on physical performance and body composition. J Am Geriatr Soc. 2005;53:2090\u20137.","journal-title":"J Am Geriatr Soc"},{"key":"200_CR22","first-page":"141","volume":"10","author":"G Godin","year":"1985","unstructured":"Godin G, Shephard RJ. A simple method to assess exercise behaviour in the community. Can J Appl Sport Sci. 1985;10:141\u20136.","journal-title":"Can J Appl Sport Sci"},{"key":"200_CR23","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s00520-013-1894-4","volume":"21","author":"RD Kilgour","year":"2013","unstructured":"Kilgour RD, Vigano A, Trutschnigg B, Lucar E, Borod M, Morais JA. Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer. 2013;21:3261\u201370.","journal-title":"Support Care Cancer"},{"key":"200_CR24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1634\/theoncologist.2017-0193","volume":"23","author":"KS Versteeg","year":"2018","unstructured":"Versteeg KS, Blauwhoff-Buskermolen S, Buffart LM, de van der Schueren MAE, Langius JAE, Verheul HMW, et al. Higher muscle strength is associated with prolonged survival in older patients with advanced cancer. Oncologist. 2018;23:580\u20135.","journal-title":"Oncologist"},{"key":"200_CR25","doi-asserted-by":"publisher","first-page":"a439","DOI":"10.1136\/bmj.a439","volume":"337","author":"JR Ruiz","year":"2008","unstructured":"Ruiz JR, Sui X, Lobelo F, Morrow JR Jr, Jackson AW, Sj\u00f6str\u00f6m M, et al. Association between muscular strength and mortality in men: prospective cohort study. BMJ. 2008;337:a439.","journal-title":"BMJ"},{"key":"200_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10522-015-9631-7","volume":"17","author":"M McLeod","year":"2016","unstructured":"McLeod M, Breen L, Hamilton DL, Philp A. Live strong and prosper: the importance of skeletal muscle strength for healthy ageing. Biogerontology. 2016;17:497\u2013510.","journal-title":"Biogerontology"},{"key":"200_CR27","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.urology.2007.09.018","volume":"71","author":"ME Levy","year":"2008","unstructured":"Levy ME, Perera S, van Londen GJ, Nelson JB, Clay CA, Greenspan SL. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study. Urology. 2008;71:735\u20139.","journal-title":"Urology"},{"key":"200_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1532-5415.2005.00530.x","volume":"54","author":"EM Simonsick","year":"2006","unstructured":"Simonsick EM, Fan E, Fleg JL. Estimating cardiorespiratory fitness in well-functioning older adults: treadmill validation of the long distance corridor walk. J Am Geriatr Soc. 2006;54:127\u201332.","journal-title":"J Am Geriatr Soc"},{"key":"200_CR29","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1001\/jama.295.17.2018","volume":"295","author":"AB Newman","year":"2006","unstructured":"Newman AB, Simonsick EM, Naydeck BL, Boudreau RM, Kritchevsky SB, Nevitt MC, et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA. 2006;295:2018\u201326.","journal-title":"JAMA"},{"key":"200_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1532-5415.2008.02126.x","volume":"57","author":"M Cesari","year":"2009","unstructured":"Cesari M, Kritchevsky SB, Newman AB, Simonsick EM, Harris TB, Penninx BW, et al. Added value of physical performance measures in predicting adverse health-related events: results from the health, aging and body composition study. J Am Geriatr Soc. 2009;57:251\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"200_CR31","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1080\/0284186X.2016.1219047","volume":"55","author":"NM Verweij","year":"2016","unstructured":"Verweij NM, Schiphorst AH, Pronk A, van den Bos F, Hamaker ME. Physical performance measures for predicting outcome in cancer patients: a systematic review. Acta Oncol. 2016;55:1386\u201391.","journal-title":"Acta Oncol"},{"key":"200_CR32","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2017.76.7400","volume":"36","author":"RU Newton","year":"2018","unstructured":"Newton RU, Taaffe DR, Chambers SK, Spry N, Galv\u00e3o DA. Effective exercise interventions for patients and survivors of cancer should be supervised, targeted, and prescribed with referrals from oncologists and general physicians. J Clin Oncol. 2018;36:927\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0200-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0200-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0200-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:34:35Z","timestamp":1684618475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-019-0200-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1038\/s41391-019-0200-z","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"20 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}